4ZELLER B, RAJANTIE J, HEDLUND-TREUTIGER I, et al. Childhood idiopathic thrombocytopenic purpura in the Nor- dic countries: epidemiology and predictors of chronic disease [J].Acta Paediatr, 2005,94(2): 178-184.
5British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thromhocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol, 2003,120(4): 574-596.
6MOUSSALEM M, YASSINE N. Immune thrombocytopenic purpura in childhood: a lebanese perspective [J]. Mol Immu- tml, 2008,39 (17 18):1105-1107.
7BERCHTOLD P, MCMILIAN R. Therapy of chronic idio- pathic thrombocytopenic purpura in adults [J].Blood, 1989,74 (7) :2309-2317.
8REIKVAM H, OLSNES A M, GJERTSEN B T, et al. Nucle- ar factor-kappa B signaling:a contributor in leukemogenesis and a target for pharmacological intervention in human acute my- elogenous leukemia [J]. Crit Rev Oncog, 2009,15(1/2) : 1-41.
9CHONG B H. Primary immune thrombocytopenia (ITP): un- derstanding pathogcnesis is the key to better treatments [J]. J Thromb Haematol, 2009,7(2) :319-321.
10EMMERICH F, BAL G, BARAKAT A, et al. High. level se- rum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura [J]. Br J Haematol, 2007,6 (2) : 309-314.
